CNSP
NASDAQCNS Pharmaceuticals Inc.
Price$2.20-4.42 (-66.77%)
2026-01-212026-04-24
News · 26 weeks32-100%
2025-11-022026-04-26
Mix1490d
- SEC Filings5(36%)
- Market4(29%)
- Insider4(29%)
- Other1(7%)
Latest news
25 items- SECSEC Form 10-K filed by CNS Pharmaceuticals Inc.10-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- SECCNS Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- NEWSCNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology PipelineNewly formed executive team initiates global search for differentiated therapeutic assets for neurology and oncology indications, two of biopharma's largest and fastest-growing marketsStrategic transformation driven by a comprehensive data analysis will enable new executive team to leverage decades of experience in these therapeutic areasCompany pivoting from a singular focus on glioblastoma and will explore out-licensing of legacy assets berubicin and TPI 287HOUSTON, TX / ACCESS Newswire / March 11, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (the "Company"), a biotechnology company focused on building a pipeline of innovative therapies in high-value neurology and oncology markets, today
- INSIDERSEC Form 4 filed by Chief Technology Officer Faulkner Eric4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 3 filed by new insider Faulkner Eric3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer O'Loughlin Steve4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 3 filed by new insider O'Loughlin Steve3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- SECCNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- NEWSCNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership TeamDr. Kelley adds two decades of highly relevant drug development and regulatory strategy experience spanning oncology, rare diseases and CNSNewly formed executive team is committed to execution and company evolution focused on patient and stakeholder valueHOUSTON, TX / ACCESS Newswire / March 2, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the appointment of Lynne Kelley, MD, FACS, as Chief Medical Officer.Dr. Kelley brings more than two decades of global leadership experience across clinical dev
- SECSEC Form S-8 filed by CNS Pharmaceuticals Inc.S-8 - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- SECCNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- NEWSCNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic TransformationNew Members of the Strengthened Leadership Team Add Decades of Operational Execution, Pipeline Optimization and Transactional Expertise to Support Company Growth and Value CreationHOUSTON, TX / ACCESS Newswire / February 17, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the Company's recently appointed President and Chief Executive officer, Rami Levin, in close alignment with the Board of Directors, has recruited key members to his new executive team. These new appointments, which will be effecti
- SECAmendment: SEC Form SCHEDULE 13G/A filed by CNS Pharmaceuticals Inc.SCHEDULE 13G/A - CNS Pharmaceuticals, Inc. (0001729427) (Subject)
- NEWSCNS Pharmaceuticals Issues Letter to ShareholdersNewly Appointed President & Chief Executive Officer, Rami Levin, Discusses Plans for a New Era at CNS PharmaceuticalsStrategic Focus, Pipeline Optimization and Formalizing Roadmap for Near and Long-Term Value CreationHOUSTON, TX / ACCESS Newswire / January 27, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today issued a Letter to Shareholders from its newly appointed President and Chief Executive Officer, Rami Levin.Dear Fellow Shareholders,I am honored to write to you for the first time in my role as President
- INSIDERSEC Form 4 filed by CEO and President Levin Rami4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 3 filed by new insider Levin Rami3 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- SECCNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- NEWSCNS Pharmaceuticals Announces CEO TransitionIndustry veteran Rami Levin, MBA appointed as President & Chief Executive OfficerHOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced John Climaco has stepped down as Chief Executive Officer of CNS Pharmaceuticals and Rami Levin, MBA, has been appointed as President & Chief Executive Officer.Mr. Levin brings nearly 30 years of global leadership experience across oncology, neurology, rare diseases, endocrinology, and cell and gene therapy, with a proven track
- SECCNS Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - CNS Pharmaceuticals, Inc. (0001729427) (Filer)
- INSIDERSEC Form 4 filed by Director Keyes Jeffry R.4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Climaco John M4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 4 filed by Director Charles Faith L.4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 4 filed by Director Mahery Amy4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Downs Christopher4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)
- INSIDERSEC Form 4 filed by Director Gumulka Jerzy4 - CNS Pharmaceuticals, Inc. (0001729427) (Issuer)